

Detailed Protocol

Each IRB submission must include a detailed protocol. For some very simple, basic studies the detailed protocol may be completely described within the IRB application. However, for most studies, including all clinical trials, a detailed protocol must be attached to the INSPIR application. For industry sponsored research the sponsored protocol usually contains all of the information required for a detailed protocol. For federally funded research, the grant proposal may contain all the information required for a detailed protocol, however, in some instances, supplemental information will be required.

Investigator initiated research proposals should include a clearly defined detailed protocol. Multi-site, investigator initiated studies should have a detailed protocol that is followed by each study site in the multi-site trial.

The following is a list of sections that should be included in a detailed protocol:

1. Background

- a. Preliminary human and animal studies
- b. References
- c. Rationale for proposed research

2. Study specific aims

- a. Hypothesis to be tested
- b. Study objectives (primary and secondary)

3. Subject selection and enrollment criteria

- a. Subject inclusion and exclusion criteria
- b. Plan for randomization and treatment assignment
- c. Inclusion of vulnerable populations
- d. Whether there are plans to translate consent and study documents

4. Recruitment and consenting

- a. Methods of recruitment
- b. Screening plans (if any)
- c. Plans for obtaining consent, plans for consent waivers, who will consent, when and how consent will be obtained
- d. Recruitment materials

5. Study procedures

- a. Clear, detailed description of all study interventions, procedures, data collection, testing
- b. Details regarding all drugs to be used (does, routes, schedules, toxicities), whether drugs are investigational, whether FDA approved, whether research will be conducted under IND, whether under 312.2
- c. Devices to be used including investigational devices, whether under IDE or 812.2
- d. Repository activities

6. Analysis

- a. Sample size justification/ power analysis
- b. Statistical methods, study endpoints
- c. Data to be collected (CRFs)

7. Risks and Discomforts

- a. Drug side effects and toxicities
- b. Potential Device problems
- c. Potential Physical Risks (including surgical risks, radiations risks including risks of MRI, CT scans, etc. performed for research purposes)
- d. Potential psycho/social risks
- e. Risks to fetus and women of childbearing potential

8. Potential Benefits

- a. Potential for direct benefits to subjects
- b. Potential for benefits to society

9. Monitoring (including Data and Safety Monitoring)

- a. Safety monitoring, evaluating of AEs and SAEs, by whom, how frequently
- b. DSMBs – charter and membership
- c. Definitions of AEs, SAEs
- d. Reporting of AEs, SAEs, Unanticipated Problems

10. Plan to protect patient privacy and confidentiality of the data

- a. Repository regarding data and specimen collection and storage
- b. HIPAA (if applicable)

11. Study Forms

- a. All questionnaires, surveys, and other data collection forms that will be used
- b. For focus groups a description of the plan for the focus group discussion
- c. Data collection forms that will be used to extract data from medical records